The Wnt signaling pathway as a target for the treatment of neurodegenerative disorders

IDrugs. 2006 Jan;9(1):35-8.

Abstract

Although significant progress in understanding brain function has been made in the last 15 years, the unmet medical need for effective therapeutic treatment of devastating neurodegenerative disorders is still enormous and represents a formidable challenge at the beginning of the 21st century. With the recent accumulation of evidence that the Wnt signaling pathway might be impaired in such diseases, a new avenue for potential therapeutic intervention has been opened which comprises many putative drug targets.

MeSH terms

  • Animals
  • Enzyme Inhibitors / pharmacology
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 beta
  • Homeostasis / physiology
  • Humans
  • Indoles / pharmacology
  • Lithium Chloride / pharmacology
  • Maleimides / pharmacology
  • Models, Biological
  • Nervous System / drug effects
  • Nervous System / embryology
  • Nervous System / growth & development
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / physiopathology
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Thiazoles / pharmacology
  • Urea / analogs & derivatives
  • Urea / pharmacology
  • Wnt Proteins / physiology*

Substances

  • Chir 99021
  • Enzyme Inhibitors
  • Indoles
  • Maleimides
  • Pyridines
  • Pyrimidines
  • SB 216763
  • Thiazoles
  • Wnt Proteins
  • N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea
  • Urea
  • Glycogen Synthase Kinase 3 beta
  • Glycogen Synthase Kinase 3
  • Lithium Chloride